Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery.

Li S, Gao J, Gu J, Yuan J, Hua D, Shen L.

Med Oncol. 2013 Jun;30(2):549. doi: 10.1007/s12032-013-0549-0. Epub 2013 Mar 27.

PMID:
23532818
2.

miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.

Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, Shen L, Yu J.

Oncogene. 2015 Jul 30;34(31):4142-52. doi: 10.1038/onc.2014.348. Epub 2014 Nov 3.

PMID:
25362853
3.

Expression pattern of miR-451 and its target MIF (macrophage migration inhibitory factor) in colorectal cancer.

Mamoori A, Gopalan V, Lu CT, Chua TC, Morris DL, Smith RA, Lam AK.

J Clin Pathol. 2017 Apr;70(4):308-312. doi: 10.1136/jclinpath-2016-203972. Epub 2016 Sep 9.

PMID:
27612504
4.

Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients.

Wang LL, Du LT, Li J, Liu YM, Qu AL, Yang YM, Zhang X, Zheng GX, Wang CX.

World J Gastroenterol. 2014 Aug 28;20(32):11340-6. doi: 10.3748/wjg.v20.i32.11340.

5.

[Association between miR-34a expression and recurrence after radical resection of colorectal cancer].

Li S, Li YY, Gao J, Shen L.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jan;16(1):60-5. Chinese.

PMID:
23355243
6.

MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.

Li PL, Zhang X, Wang LL, Du LT, Yang YM, Li J, Wang CX.

Carcinogenesis. 2015 Dec;36(12):1484-93. doi: 10.1093/carcin/bgv145. Epub 2015 Oct 6.

PMID:
26442524
7.

MicroRNA expression profile in patients with stage II colorectal cancer: a Turkish referral center study.

Tanoglu A, Balta AZ, Berber U, Ozdemir Y, Emirzeoglu L, Sayilir A, Sucullu I.

Asian Pac J Cancer Prev. 2015;16(5):1851-5.

8.

Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer.

Zhou T, Zhang G, Liu Z, Xia S, Tian H.

Int J Colorectal Dis. 2013 Jan;28(1):19-24. doi: 10.1007/s00384-012-1528-1. Epub 2012 Jul 7.

PMID:
22772712
9.

Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients.

Diamantopoulos MA, Kontos CK, Kerimis D, Papadopoulos IN, Scorilas A.

Clin Chem Lab Med. 2017 May 1;55(5):737-747. doi: 10.1515/cclm-2016-0756.

PMID:
27930363
10.

Prognostic significance of microRNA-16 expression in human colorectal cancer.

Qian J, Jiang B, Li M, Chen J, Fang M.

World J Surg. 2013 Dec;37(12):2944-9. doi: 10.1007/s00268-013-2205-4.

PMID:
24045965
11.

The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer.

Bovell LC, Shanmugam C, Putcha BD, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE, Manne U.

Clin Cancer Res. 2013 Jul 15;19(14):3955-65. doi: 10.1158/1078-0432.CCR-12-3302. Epub 2013 May 29.

12.

Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma.

Kerimis D, Kontos CK, Christodoulou S, Papadopoulos IN, Scorilas A.

Clin Biochem. 2017 Apr;50(6):285-292. doi: 10.1016/j.clinbiochem.2016.11.034. Epub 2016 Dec 7.

PMID:
27939727
13.

The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.

Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, Boland CR, Goel A.

PLoS One. 2012;7(10):e46684. doi: 10.1371/journal.pone.0046684. Epub 2012 Oct 3.

14.

Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma.

Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, Lin L, You P, Li J, Dai Z, Liang X, Su Y, Hu Q, Wang F, Zhang ZY.

J Exp Clin Cancer Res. 2015 Aug 22;34:86. doi: 10.1186/s13046-015-0198-6.

15.

Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.

Chen Q, Xia HW, Ge XJ, Zhang YC, Tang QL, Bi F.

Asian Pac J Cancer Prev. 2013;14(12):7421-6.

16.

Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer.

Wang X, Wang J, Ma H, Zhang J, Zhou X.

Med Oncol. 2012 Jun;29(2):919-27. doi: 10.1007/s12032-011-9880-5. Epub 2011 Mar 10.

PMID:
21390519
17.

miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer.

Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W, Qin H.

Gut. 2012 Oct;61(10):1447-53. doi: 10.1136/gutjnl-2011-301122. Epub 2011 Nov 3.

PMID:
22052060
18.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

19.

Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.

Fukushima Y, Iinuma H, Tsukamoto M, Matsuda K, Hashiguchi Y.

Oncol Rep. 2015 Feb;33(2):573-82. doi: 10.3892/or.2014.3614. Epub 2014 Nov 21.

PMID:
25421755
20.

[Expression of microRNA-152 in colorectal cancer and its relationship with prognosis].

Wang Y, Yuan W, Ma X, Ma J.

Zhonghua Zhong Liu Za Zhi. 2016 Oct 23;38(10):763-766. doi: 10.3760/cma.j.issn.0253-3766.2016.10.010. Chinese.

PMID:
27784461

Supplemental Content

Support Center